Point-Counterpoint: US FDA Adcomm Joint Briefing Document Likely Limited To Oncology For Now

 
• By Sue Sutter
Debate podiums
There are differences of opinion on use of a joint FDA-sponsor briefing document for advisory committee meetings. • Source: Shutterstock

More from US FDA Performance Tracker

More from Regulatory Trackers